Advertisement

Relatlimab and Nivolumab vs Nivolumab Alone in Untreated Advanced Melanoma
Posted: 01/11/2022 | By: Sarah Campen, PharmD

Question 1 of 5

The median progression-free survival in the two treatment arms was:

Choose 1

A
Not reached in the relatlimab/nivolumab group vs 8.2 months in the nivolumab monotherapy group
B
15.4 months in the relatlimab/nivolumab group vs 11.8 months in the nivolumab monotherapy group
C
10.1 months in the relatlimab/nivolumab group vs 4.6 months in the nivolumab monotherapy group
D
Not significantly different between the two treatment groups

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage